Updates ·
Health notices · Tuesday 27 October
3 notices from the agencies today, in plain words, each with the original linked.
Recall class issued for tirzepatide/niacinamide injection vials
Food and Drug Administration (FDA) · Recall
If you have received tirzepatide/niacinamide injection vials (2 mL) from Houston RX LLC, this FDA Class II recall may affect you.
The reason given is lack of assurance of sterility, meaning there is not enough confirmation the product is free from harmful germs.
Yellow Card updates for #MedSafetyWeek reporting
Medicines and Healthcare products Regulatory Agency (MHRA) · Safety
If you use medicines, vaccines, or medical devices (including e-cigarettes/vapes), #MedSafetyWeek (2 to 8 November 2026) highlights reporting suspected side effects and safety concerns through Yellow Card.
A Yellow Card is a report of a suspected side effect or safety concern. Reporting helps MHRA identify and monitor potential safety issues so patients can be protected.
The Yellow Card website and app have updates, including National Health Service (NHS) Login for easier access and an app that works as a progressive web app with real-time updates.
What to do
- Report suspected side effects or safety concerns using the Yellow Card website (yellowcard.mhra.gov.uk) or the Yellow Card app (yellowcard.mhra.gov.uk/app).
FDA class II recall of metoclopramide 5 mg tablets due to foreign tablets
FDA · Recall
If you take metoclopramide tablets (5 mg) made for Teva and sold nationwide, the FDA has issued a class II recall.
The problem is the presence of foreign tablets/capsules in some bottles of metoclopramide.
The recall covers specific product identifiers listed in the notice and was published on 2026-10-21.
The notice provided does not include specific steps for patients, so check your bottle details against the notice and follow your pharmacist’s or prescriber’s guidance.